Drugs / Rebastinib
Rebastinib
also known as
DCC-2036 · DCC-2036 FREE BASE · DP-1919 · DP-1919.TO · Dp-1919.to, dcc-2036 · Rebastinib tosilate · REBASTINIB TOSYLATE
Small molecule targets ABL1, KDR, LYN via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02824575 | Jul 2016 → Dec 2021 | Her2-receptor negative breast cancer, breast adenocarcinoma | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00827138 | Mar 2009 → Jan 2013 | chronic myeloid leukemia | Deciphera Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03717415 | Jan 2019 → May 2022 | — | Deciphera Pharmaceuticals, LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT03601897 | Oct 2018 → May 2022 | — | Deciphera Pharmaceuticals, LLC | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2021-09-17 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021 deciphera.com ↗
Rebastinib in Combination with Paclitaxel Demonstrated Progression Free Survival of 9.1 months in Heavily Pretreated Patients with Platinum-Resistant Ovarian Cancer (PROC) |
| 2021-06-04 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting deciphera.com ↗
Rebastinib in Combination with Paclitaxel in a Phase 1b/2 Study Demonstrated Median Progression Free Survival of 6.2 Months in Heavily Pretreated Patients with Endometrial Cancer |
| 2020-09-17 | Deciphera Pharmaceuticals, LLC | Results Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 deciphera.com ↗
Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer |
| 2020-05-29 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific Program deciphera.com ↗
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of data from the endometrial cancer cohort of Part 2 of its ongoing Phase 1b/2 clinical trial of rebastinib, the Company’s investigational orally administered, potent and selective inhibitor of the TIE-2 kinase, in combination with paclitaxel. |
| 2019-10-28 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics deciphera.com ↗
Combination of Rebastinib and Paclitaxel Exhibited Encouraging Preliminary Anti-tumor Activity Across Treatment Arms in the Ongoing Phase 1b/2 Clinical Study |
| 2015-04-22 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Presents Data Highlighting Kinase Inhibitor Pipeline including Proprietary and Partnered Programs at AACR 2015 Annual Meeting deciphera.com ↗
Preclinical data demonstrate robust and durable kinase inhibition to block key cancer signaling mechanisms targeting the tumor cell and the tumor microenvironment |
| 2014-03-17 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Presents Preclinical Data on Rebastinib and DCC-3014 at AACR Tumor Microenvironment Conference deciphera.com ↗
Rebastinib potently inhibited TIE2 kinase in cellular assays and blocked primary tumor growth by 75% as a single agent and by 90% in combination with the standard chemotherapeutic agent paclitaxel in the PyMT mouse breast cancer model. |
| 2011-04-18 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Announces DCC-2036 research for CML published in Cancer Cell deciphera.com ↗
Research from Deciphera Pharmaceuticals was published this week disclosing that a novel drug, DCC-2036, shows promise for treating chronic myelogenous leukemia (CML) patients who have few other options because their disease has developed resistance to standard treatments. |
All press releases naming this drug 13 releases
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rebastinib | “Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.” PMID 27927766 ↗ Dec 2016 |
| Known as | DCC-2036 | “A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors” NCT03717415 ↗ |
| Known as | DCC-2036 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | DP-1919 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | DP-1919.TO | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | Dp-1919.to, dcc-2036 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | Rebastinib tosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | REBASTINIB TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Action | Inhibit | “DCC-2036 is a potent broad spectrum inhibitor of BCR-ABL kinase.” NCT00827138 ↗1“Tyrosine-protein kinase ABL inhibitor” CHEMBL1738757 ↗ |
| Modality | Small molecule | — CHEMBL1738757 ↗ |
| Route | Oral | “150 mg BID tablets, continuous dosing of 28 day cycles” NCT00827138 ↗ |
| Target | ABL1 | “Tyrosine-protein kinase ABL inhibitor” CHEMBL1738757 ↗ |
| Target | KDR | “DCC-2036 also inhibits FLT3-ITD, TIE2, KDR, LYN and TRKA kinases.” NCT00827138 ↗ |
| Target | LYN | “DCC-2036 also inhibits FLT3-ITD, TIE2, KDR, LYN and TRKA kinases.” NCT00827138 ↗ |